<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04748796</url>
  </required_header>
  <id_info>
    <org_study_id>PI2020_843_0057</org_study_id>
    <nct_id>NCT04748796</nct_id>
  </id_info>
  <brief_title>Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility</brief_title>
  <acronym>HyperBetashock</acronym>
  <official_title>Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility: an Open Label Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CH Dieppe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH Elbeuf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH Le Havre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Beauvais</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH Compiègne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH Laon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH Cherbourg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH Douai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH Montreuil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Roubaix</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Bethune</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH Lomme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Lens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tourcoing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier VALENCIENNES</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Arras</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Ambroise Paré Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henri Mondor University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Avicenne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH Calais</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Edouard Herriot</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupe Hospitalier Pitié-Salpêtrière</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several data emphasize the relation between tachycardia (&gt;90/min) and high mortality during&#xD;
      septic shock. The investigators previously demonstrated the high mortality associated with&#xD;
      hypercontractility, tachycardia and the presence of a left ventricular obstruction. A severe&#xD;
      hypovolemia, a hyper adrenergic stimulation or a severe vasoplegia can all explain this&#xD;
      relation between tachycardia, hypercontractility and the mortality during septic shock.&#xD;
&#xD;
      Landiolol is another short-term acting beta-blocker with a half-life of 4 minutes without any&#xD;
      beta 2 activity or membrane stabilizing effect. The landiolol has been used in critically ill&#xD;
      patients to control supraventricular tachycardia but not in this context of tachycardia and&#xD;
      septic shock. The investigators hypothesize that landiolol by reducing the heart rate may&#xD;
      improve the survival of patients treated for a septic shock and presenting with an&#xD;
      hypercontractility state.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of mortality rate in landiolol group compared to control group</measure>
    <time_frame>day 28</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Septic Shock</condition>
  <condition>Tachycardia</condition>
  <condition>Mortality During Septic Shock</condition>
  <condition>Beta-blocker</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 days with landiolol IV + usual care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>usual care according to the attending physician and following the guidelines of surviving sepsis campaign.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>echocardiography</intervention_name>
    <description>Full echocardiography will be performed at baseline and during the follow-up at H1, H3, H6 and H12.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Landiolol</intervention_name>
    <description>Patients randomized to the experimental group will be treated according to the standard of care plus for 2 days with landiolol IV started at a dose of 1 microgram/kg/min and progressively increased every 10 minutes to a maximum of 40 micrograms/kg/min.</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  Patient admitted for a septic shock (according to the SEPSIS3 definition: sepsis with&#xD;
             persisting hypotension (MAP&lt;65mmHg or SAP &lt;90mmHg) requiring vasopressors to maintain&#xD;
             MAP&gt;65mmHg and having a serum lactate level &gt;2 mmol/L&#xD;
&#xD;
          -  Patient who received at least 30ml/kg of fluid and absence of fluid responsiveness&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt;65% (visual or Simpson method using&#xD;
             echocardiography)&#xD;
&#xD;
          -  Tachycardia &gt;100 bpm in sinus rhythm with a MAP 65mmHg for more than 1 hour&#xD;
&#xD;
          -  Patient receiving invasive mechanical ventilation&#xD;
&#xD;
          -  Patients adapted to the ventilator under sedation and analgesia&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Patient covered by French national health insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with inclusion criteria already present for more than 36 hours&#xD;
&#xD;
          -  Patient treated with Dobutamine, adrenaline or isoprenaline&#xD;
&#xD;
          -  Patient currently treated with beta blockers (previous home betablocker treatment is&#xD;
             not an exclusion criteria)&#xD;
&#xD;
          -  Supra ventricular (atrial fibrillation or flutter) or ventricular arrhythmias&#xD;
&#xD;
          -  Patients with any form of cardiac pacing&#xD;
&#xD;
          -  Sick sinus syndrome&#xD;
&#xD;
          -  Severe atrioventricular (AV) nodal conductance disorders (without pacemaker): 2nd or&#xD;
             3rd degree AV block&#xD;
&#xD;
          -  Known pulmonary hypertension&#xD;
&#xD;
          -  ScVO2 &lt;70%&#xD;
&#xD;
          -  Moribund&#xD;
&#xD;
          -  Cardiac arrest&#xD;
&#xD;
          -  Non-treated phaeochromocytoma&#xD;
&#xD;
          -  Acute asthmatic attack&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Patient deprived of liberty by administrative or judicial decision or placed under&#xD;
             judicial protection (guardianship or supervision),&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Hypersensitivity to the active substance or to any of the excipients&#xD;
&#xD;
          -  Severe bradycardia (less than 50 beats per minute)&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Severe hypotension&#xD;
&#xD;
          -  Decompensated heart failure when considered not related to the arrhythmia&#xD;
&#xD;
          -  Severe, uncorrectable metabolic acidosis&#xD;
&#xD;
          -  Presence of significant bleeding, or&#xD;
&#xD;
          -  Acute respiratory distress defined by increased oxygen dependency, polypnea &gt; 30 /min,&#xD;
             signs of struggle (pulling, thoraco-abdominal sway) if the patient is not intubated&#xD;
             and ventilated.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Slama Michel, Pr</last_name>
    <phone>03 22 08 78 41</phone>
    <email>slama.michel@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Slama, Pr</last_name>
      <phone>(33)3 22 08 78 41</phone>
      <email>slama.michel@chu-amiens.fr</email>
    </contact>
    <contact_backup>
      <last_name>Julien Maizel, Pr</last_name>
      <phone>(33)3 22 08 78 07</phone>
      <email>maizel.julien@chu-amiens.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Julien Maizel, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Herve Dupont, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Louis DECLERCQ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Louis CHAUVET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mehdi BOUSTA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David LUIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geneviève BARJON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eloi GOULLIEUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damien DU CHEYRON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bertrand SAUNEUF, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saad NSEIR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe MOREL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérôme LEPRETRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick HERBECQ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe VINSONNEAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry VANDERLINDEN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier THEVENIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier LEROY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabien LAMBIOTTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maxime GRANIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoine VIEILLARD BARON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gwenael PRAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Armand MEKONTSO DESSAP, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephane GAUDRY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kada KLOUCHE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph BAYEKULA MAFULA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard ALLAOUCHICHE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent MULLER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Michel CONSTANTIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Septic Shock</keyword>
  <keyword>Tachycardia</keyword>
  <keyword>mortality during septic shock</keyword>
  <keyword>beta-blocker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Landiolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

